期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

生物大分子药物洗脱冠状动脉支架 被引量：1

Biomacromolecule-eluting Stent for Coronary Artery Disease
下载PDF
导出
摘要 生物大分子药物洗脱支架是指载有核酸、抗体、酶、细胞因子等活性生物大分子的冠状动脉支架。生物大分子可针对再狭窄的分子机制,作用于指定环节的特定靶点,具有高度特异性,因此生物大分子药物洗脱支架可望成为解决支架内再狭窄和晚期血栓的根本途径。文章就目前生物大分子药物洗脱支架国内外最新研究进展作一综述。 As with drug-eluting stents （DES）, biomacromolecule-eluting stents can deliver biologically active agents such as nucleic acid, antibody, enzyme and cell factor. Biological active agents can selectively act at specific target location through molecular mechanism of coronary artery restenosis. This seems to be a promising treatment strategy for preventing in-stent restenosis （ISR） while simultaneously reducing the risk of stent thrombosis. This article reviews recent developments in biomacromolecule-eluting stents.
作者 张超 宋存先 孙洪范 马桂蕾
机构地区 中国医学科学院北京协和医学院生物医学工程研究所
出处 《中国动脉硬化杂志》 CAS CSCD 北大核心 2013年第3期275-279,共5页 Chinese Journal of Arteriosclerosis
基金 国家自然科学基金资助项目(50830106 50903093)
关键词 药物洗脱支架 再狭窄 血栓 内皮化 生物大分子 基因递送 Drug-eluting Stent In-stent Restenosis Thrombosis Endothelialization Biomacromolecule Gene Delivery
分类号 R972 [医药卫生—药品]
  • 相关文献

参考文献31

  • 1Butt M, Connolly D, Lip GY. Drug-eluting stents: a comprehensive appraisal [ J ]. Future Cardiol, 2009 ; 5 ( 2 ) : 141-157.
  • 2Martin DM, Boyle FJ. Drug-eluting stents for coronary artery disease: a review [ J ]. Med Eng & Phys, 2011, 33 (2) : 148-163.
  • 3Luscher TF, Steffel J, Eberli FR, etal. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications [ J ]. Circulation, 2007, 115 ( 8 ) : 1 051-058.
  • 4Al-Dehneh A, Virk H, Alkhouri Y, et al. Drug-eluting stent thrombosis 1659 days after stent deployment: case report and literature review [ J]. Tex Heart Inst J, 2010, 37 ( 3 ) : 343-346.
  • 5Hironobu T, Didier L, David WG. Delivery of large biopharmaceuticals from cardiovascular stents: a review [ J ]. Biomacromolecules, 2007, 8( 11 ) : 3 281-293.
  • 6Beijk MA, Klomp M, van Geloven N, et al. Two-year follow-up of the GenousTM endothelial progenitor cell capturing stent versus the Taxus Liberte stent in patients with de novo coronary artery lesions with a high-risk of restenosis : a ran- domized, single-center, pilot study [ J ]. Catheter Cardiovasc Interv, 2011, 78(2) : 189-195.
  • 7Klomp M, Beijk MA, Damman P, et al. Three-year clinical follow-up of an unselected patient population treated with the genous endothelial progenitor cell capturing stent [J]. J Interv Cardiol, 2011, 24(5) : 442-449.
  • 8Swanson N, Hogrefe K, Javed Q, et al. Vascular endothelial growth factor (VEGF)-eluting stents: in vivo effects on thrombosis, endothelialization and intimal hyperplasia [ J ]. J Invasive Cardiol, 2003, 15 (12) : 688-692.
  • 9Walter DH, Cejna M, Diaz-Sandoval L, et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis [ J ]. Circulation, 2004, 110(1): 36-45.
  • 10Xu H, Nguyen KT, Brilakis ES, et al. Enhanced endothelialization of a new stent polymer through surface enhancement and incorporation of growth factor-delivering microparticles [ J]. J Cardiovasc Transl Res, 2012, 5 (4) : 519-527.

二级参考文献17

  • 1Sharif F, Daly K, Crowley J, et al. Current status of catheter-and stent-based gene therapy[J]. Cardiovasc Res, 2004, 64(2): 208-216.
  • 2Awata M, Kotani J, Uematsu M, et al. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implan- tation: comparison with bare-metal stents[J]. Circulation, 2007, 116 (8): 910-916.
  • 3Daemen J, Wenaweser P, Tsuehida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study[J]. Lancet, 2007, 369(9562): 667-678.
  • 4Ellis SG, Colombo A, Grube E, et al. Incidence, timing, and corre- lates of stent thrombosis with the polymeric paclitaxel drug-eluting stent: a TAXUS II, IV, V, and VI meta-analysis of 3,445 patients fol- lowed for up to 3 years[J]. J Am Coll Cardiol, 2007, 49 (10): 1043- 1051.
  • 5Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial[J]. Circulation, 2004, 109(16): 1942-1947.
  • 6Johnson TW, Wu Yin-xiong, Herdeg C, et al. Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries[J]. Arterioscler Thromb Vasc Biol, 2005, 25(4): 754-759.
  • 7Takahashi A, Palmer-Opolski M, Smith RC, et al. Transgene delivery of plasmid DNA to smooth muscle cells and macrophages from a biostable polymer-coated stent[J]. Gene Ther, 2003, 10 (17): 1471- 1478.
  • 8Jewell CM, Zhang Jing-tao, Fredin NJ, et al. Release of plasmid DNA from intravascular stents coated with ultrathin multilayered polyelec- trolyte films[J]. Biomacromolecules, 2006, 7(9): 2483-2491.
  • 9Kopp CW, de Martin R. Gene therapy approaches for the prevention of restenosis[J]. Curt Vasc Pharmacol, 2004, 2(2): 183-189.
  • 10Numaguchi Y, Okumura K, Harada M, et al. Catheter-based prosta- cyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries[J]. Cardiovasc Res, 2004, 61(1): 177-185.

同被引文献47

引证文献1

二级引证文献9

中国动脉硬化杂志
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部